Excision BioTherapeutics
Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).
HIV-1-infection
EBT-101
Phase 1
Participants who receive EBT-101 in a parent protocol will be eligible to participate in this LTFU study (EBT-101-002). All participants will have follow-up visits every six months until Year 5 post EBT-101. Thereafter, all participants will have follow-up visits annually on the anniversary of EBT-101 administration until study completion at Year 15.}}
| Study Type : | Interventional |
| Estimated Enrollment : | 9 participants |
| Masking : | None (Open Label) |
| Primary Purpose : | Other |
| Official Title : | Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Parent Study Where EBT-101 Was Administered |
| Actual Study Start Date : | July 11, 2023 |
| Estimated Primary Completion Date : | January 2037 |
| Estimated Study Completion Date : | April 2037 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Long Term Follow Up Participants who received EBT-101 in a parent study will undergo long term follow up |
Biological: EBT-101 |
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Quest Clinical Research
San Francisco, California, United States, 94115
Not yet recruiting
Washington University
Saint Louis, missouri, United States, 63110
Not yet recruiting
Cooper Health
Camden, New Jersey, United States, 08103